LUPUS ERYTHEMATOSUS, SYSTEMIC

This study follows 218 adults with lupus in Italy who are starting a drug called anifrolumab. The goal is to see if they can reach a state of low disease activity while taking a low dose of steroids (5 mg or less per day) after one year. Researchers will track how many patients a…

This study follows 100 Polish adults with systemic lupus erythematosus (SLE) who are receiving anifrolumab as part of their routine care. Researchers will track changes in disease activity and overall health over time to see how well the treatment works in real-world settings. Th…

This study tests a new drug called cenerimod for people with lupus who have active kidney inflammation (lupus nephritis). About 300 adults will take either cenerimod or a placebo daily for 76 weeks, on top of their usual treatments. The goal is to see if cenerimod can improve kid…

This study looks at how well the drug anifrolumab works for adults with lupus when used in normal doctor visits. About 125 people will receive the drug as a shot under the skin. Researchers will track if patients can reach a state of low disease activity or remission over two yea…

This study tests a one-time treatment called rapcabtagene autoleucel for people with active lupus or lupus kidney disease that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab, to target and calm the overactive immune syst…

This early-stage study tests a new treatment called CTX112 for people with severe autoimmune diseases like lupus, scleroderma, or myositis that haven't improved with standard therapies. CTX112 uses specially engineered immune cells from a donor to target and attack faulty immune …

This study tests a new treatment called CC-97540 for people with active lupus, including lupus nephritis, who haven't gotten better with standard medicines. The treatment uses specially engineered immune cells (CAR T cells) to target and destroy faulty immune cells causing the di…

This study tests a new treatment called AZD0120 for adults with severe lupus that hasn't improved with standard therapies. AZD0120 uses a patient's own immune cells, modified to target and destroy faulty cells that drive lupus. The trial will check safety and whether it can reduc…

This study tests whether nipocalimab can reduce lupus disease activity better than a placebo. About 600 adults with moderate to severe lupus will receive either the drug or a placebo for 52 weeks. The main goal is to see if more people on nipocalimab achieve a meaningful reductio…

This study looks at how three different levels of physical activity (45, 90, or 150 minutes per week) affect arthritis symptoms like pain and physical function. Researchers will enroll 285 adults with arthritis, rheumatoid arthritis, gout, fibromyalgia, osteoarthritis, or lupus. …

This study tests whether a short behavioral treatment delivered over Zoom can help adults with fibromyalgia, lupus, chronic pelvic pain, or chronic low back pain learn ways to reduce pain and disability. About 125 participants will take part. The goal is to see if this approach i…

This study aims to find a way to predict serious side effects from cancer immunotherapy. Researchers will measure substances called interferons in the blood of 300 cancer patients starting immunotherapy and 40 people with autoimmune diseases like lupus. By comparing these groups,…

This study looks at how natural cannabis compounds (phytocannabinoids) affect immune cells from 100 people with chronic inflammatory diseases like rheumatoid arthritis, lupus, and inflammatory bowel disease. Researchers will take blood samples and expose the cells to different ca…